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were randomized to either twice daily exenatide (N = 228) or
once daily glargine (N = 227) during the 26-week, non-
inferiority trial. The Vitality Scale of the Short Form 36, The Dia-
betes Symptom Checklist—Revised, The EuroQol instrument
(EQ-5D), The Treatment Flexibility Scale, and The Diabetes
Treatment Satisfaction Questionnaire (DTSQ) were administered
at baseline and endpoint. Change from baseline to endpoint was
compared within each treatment, and then between treatment
groups with analysis of covariance models, controlling for
country and baseline scores. RESULTS: At endpoint, exenatide
and glargine achieved similar HbA1c reductions. In each patient
reported outcome instrument, both treatment groups improved
from baseline to endpoint; however no statistically signiﬁcant
differences were observed between the treatment groups. Because
exenatide was associated with a higher incidence of nausea, the
impact of treatment satisfaction, as measured by the DTSQ, was
assessed for those exenatide patients who experienced nausea
during the trial (n = 126). These patients demonstrated improve-
ment from baseline to endpoint as well. CONCLUSIONS: Both
injectable medications signiﬁcantly improved the quality of life
when added to pre-existing oral therapy. Exenatide, injected
twice daily, was associated with an elevated incidence of nausea.
However, despite the addition of an injection requirement and
side effect of nausea, treatment satisfaction in exenitide group
was comparable to that of the glargine group.
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OBJECTIVE: In addition to weight reduction, there may be
other beneﬁts of obesity treatment including improved insulin
sensitivity. The purpose of this study was to characterise con-
comitant diabetes drug use and the related costs in diabetic
patients treated with orlistat in the ﬁrst six months of weight
management. METHODS: One hundred overweight diabetic
patients were enrolled in a structured weight management clinic
and treated with orlistat plus behavioural interventions. Among
other measures, weight, glucose control (HbA1c) and drug treat-
ments were recorded. Subjects were followed-up for a maximum
of 24 months at intervals of 6 months, with a maximum treat-
ment period of 24 months. RESULTS: The majority of subjects
(90%) had type-2 diabetes. They had a median age of 55 years
(IQR 47–63) and 55% were women. The mean BMI at baseline
was 39.51 with a mean HbA1c of 7.56%. The mean reduction
in weight at 6 months was 7.1kg (p < 0.001), with an average
absolute HbA1c improvement of 0.62% (p < 0.001). Of the 50
patients treated with insulin at baseline, three no longer required
insulin by the 6 month follow up. Of those treated with insulin,
the mean insulin dose was 130 iu (SD 135.4) at baseline and 
90 iu (SD 125.4) at 6 months (p < 0.001). Twenty patients (45%)
initially treated with oral hypoglycaemic agents alone reduced
their dose after 6 months. Despite marked improvement in
insulin sensitivity (baseline mean 1.24 iu/kg: 6 month mean 
0.90 iu/kg (p < 0.001)) there was no correlation with BMI
change. The average cost of diabetes treatment was £0.82 per
day at baseline and £0.59 at 6 months (D 28%; p < 0.001). CON-
CLUSIONS: Orlistat therapy, in conjunction with a structured
weight management programme, appears to reduce the need for
concomitant diabetes medication irrespective of weight loss. This
reduction is likely to translate into a large cost offset for orlistat
treatment.
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OBJECTIVES: To examine the effects of orlistat and rosiglita-
zone and assess the changes of cardiovascular risk factors in a
group of Chinese patients affected by the metabolic syndrome.
METHODS: In a prospective, 6-months randomized single-
blinded placebo-controlled study, 58 Chinese participants with
type-2 diabetes or impaired glucose tolerance, aged >18 years
with a BMI of 23kg/m2 or above were administered orally 
120mg orlistat three times daily, rosiglitazone 2mg twice daily
or placebo three times daily. Changes in clinical and metabolic
parameters of the metabolic syndrome were monitored, includ-
ing BMI, body fat, glycaemic control, lipid levels and drug tol-
erability. RESULTS: There were 20 individuals in the
rosiglitazone group and 19 individuals in both the orlistat and
placebo groups. There were statistically signiﬁcant differences
between the three groups in total cholesterol (p = 0.001), triglyc-
erides (p = 0.037), LDL-cholesterol (p = 0.001), BMI (p = 0.001),
hip (p = 0.002) and body fat (p = 0.006). The orlistat group
demonstrated improved lipid proﬁles from baseline, especially on
the reduction of total cholesterol (12% p = 0.0005) and LDL
(21%, p = 0.0002). This was accompanied by improvements in
the fasting insulin levels (p = 0.07) and Homeostatic Model
Assessment (HOMA) scores (p = 0.026). In comparison, the
rosiglitazone group exhibits maximum improvements in fasting
insulin (p = 0.004), 2hr-post OGTT insulin (p = 0.004) and
HOMA scores (p = 0.005). Although statistically insigniﬁcant,
there is a slight increase from baseline in the LDL levels (12%)
and body fat (3.7%). CONCLUSIONS: To prevent progression
to type-2 diabetes mellitus and its complications, early detection
and implementation of appropriate treatment strategies for the
metabolic syndrome is crucial. Both rosiglitazone and orlistat
appear to be promising in treating the metabolic syndrome.
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OBJECTIVES: To assess the clinical beneﬁts of add-on treatment
with Niaspan® (increases HDL-c) or ezetimibe (reduces LDL-c)
on coronary heart disease (CHD) in Type-2 diabetes patients
failing to reach target cholesterol levels on statin monotherapy.
METHODS: Two models were developed to project the clinical
beneﬁts of treatment over 10 years. The ﬁrst model (Monte Carlo
simulation) was used to evaluate the impact of simvastatin treat-
ment on lipid levels and identify patients with low HDL-c or high
LDL-c. Baseline cohort characteristics were taken from the 
diabetic sub-population of the 4S study. Patients with LDL-c 
<3mmol/L and HDL-c <1mmol/L received add-on Niaspan®.
Patients with LDL-c >3mmol/L received add-on ezetimibe. Each
add-on treatment was compared to statin monotherapy. Treat-
ment effects for both drugs were taken from several clinical trials
summarized in the European SPC. The second model (Markov
model) was used to evaluate the cumulative incidence of CHD
A157Abstracts
events. Transition probabilities were based on Framingham risk
formulae. RESULTS: Over 10 years, in Type-2 diabetes patients
with controlled LDL-c and low HDL-c (<1mmol/L), addition of
Niaspan® (2g daily) to statin treatment was projected to reduce
the absolute incidence of MI (3.2%), angina (0.7%) and CHD
death (1.6%) compared to statin monotherapy. Relative risk
reductions were 13.3%, 12.5% and 13.1% respectively. In
patients with elevated LDL-c (>3mmol/L), ezetimibe plus statin
was associated with a reduced absolute incidence for MI (2.3%),
angina (0.5%) and CHD death (1.1%) versus statin alone. Rel-
ative risk reductions were 7.7%, 7.4% and 7.9% respectively.
CONCLUSIONS: Over 10 years, both Niaspan® and ezetimibe
may lead to substantial reductions in the cumulative incidence
of CHD events in Type-2 diabetes patients failing to reach cho-
lesterol targets with statin monotherapy. These ﬁndings highlight
the potential long-term beneﬁts of raising HDL-c in Type-2 dia-
betes patients with controlled LDL-c.
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OBJECTIVES: To evaluate the clinical beneﬁts of raising HDL-
c by adding Niaspan® on coronary heart disease (CHD) end-
points in Type-2 diabetes patients on statin therapy. METHODS:
Two successive models were developed to project long-term clin-
ical beneﬁts of treating patients over different time periods. The
ﬁrst model (Monte Carlo simulation) was used to evaluate the
impact of simvastatin treatment on lipid levels and identify
patients with low HDL-c. Baseline cohort characteristics and
effects of statin treatment were taken from the diabetic sub-
population of the 4S study. In patients with HDL-c <1mmol/L,
treatment with statin plus add-on Niaspan® was compared to
statin monotherapy. Niaspan® treatment effects were taken from
several clinical trials as summarized in the European SPC. The
second model was then used to simulate the development of
CHD events based on the Framingham risk formulae. This
Markov model included ﬁve states: no CHD, history of myocar-
dial infarction (MI), history of MI and angina, and dead. Cycle
length was one year. RESULTS: Addition of Niaspan® (2g daily)
to statin treatment was associated with a lower cumulative inci-
dence of CHD events than statin monotherapy. Absolute risk
reductions of 2.1%, 4.0%, and 8.1% for myocardial infarction,
0.5%, 0.9%, and 1.3% for angina, and 1.0%, 1.9%, and 4.0%
for CHD death were projected at time horizons of 5, 10, and 
35 years respectively. CONCLUSIONS: Due to its positive effect
on HDL-c levels, addition of Niaspan® to statin treatment was
projected to reduce the cumulative incidence of CHD events
compared to statin monotherapy in type-2 diabetes patients 
with persistently low HDL-c. These data indicate that as the
treatment period increases, the clinical beneﬁts associated 
with statin plus Niaspan® may also increase compared to statin
monotherapy.
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OBJECTIVE: Type-2 diabetes is recognized as a growing
problem across the world, with the number of individuals diag-
nosed with this disorder expected to approximately double in the
next 25 years. The objective of this study is to examine the preva-
lence of Type-2 diabetes as well as trends in antidiabetic med-
ication use in Germany. METHODS: Data for this study were
obtained from the German Disease Analyzer—Mediplus data-
base. All patients who were identiﬁed with Type-2 diabetes
between 01/01/2001 and 12/31/2003 and who were at least 20
years of age when ﬁrst identiﬁed as having Type-2 diabetes were
included in the prevalence estimate (N = 45988). While the 2003
prevalence estimate was based on data from a three year window,
patient characteristics and medication use was examined for each
of the three calendar years. These cohorts consisted of patients
identiﬁed with Type-2 diabetes who were at least age 20 during
the year (N = 20766 for 2001; N = 22778 for 2002; and N =
23326 for 2003). RESULTS: The prevalence of Type-2 diabetes
was estimated to be 3.93% in 2003. From 2001 to 2003, there
was a decrease in the percentage of patients with Type-2 diabetes
who were not receiving antidiabetic medication (from 34.28%
to 28.27%; p < 0.0001) as well as a signiﬁcant decrease in the
use of sulfonylureas (from 20.02% to 16.02%; p < 0.0001). In
contrast, there were signiﬁcant increases in monotherapy insulin
use (from 7.95% to 9.90%; p < 0.0001), monotherapy met-
formin use (from 14.04% to 18.71%; p < 0.0001), and oral com-
bination antidiabetic medication use (from 14.34% to 16.99%;
p < 0.0001) over the same time period. CONCLUSIONS: The
prevalence estimate conﬁrms that Type-2 diabetes is a signiﬁcant
health concern in Germany. Furthermore, recent trends demon-
strate that physicians are increasingly likely to prescribe antidi-
abetic therapies for the treatment of this disease.
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